{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:58:41Z","timestamp":1760061521086,"version":"3.44.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,25]]},"DOI":"10.7759\/cureus.90944","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T13:35:19Z","timestamp":1756128919000},"source":"Crossref","is-referenced-by-count":1,"title":["Grade 4 Mucositis Secondary to Methotrexate Use in a Pediatric Patient With Stage IV Burkitt Lymphoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Fadia Y","family":"Abdala Mendoza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Circe","family":"Ancona Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1989.286","article-title":"Involvement of the ileocaecal region by non-Hodgkin's lymphoma in adults: clinical features and results of treatment","volume":"60","author":"Sweetenham JW","year":"1989","unstructured":"Sweetenham JW, Mead GM, Wright DH, McKendrick JJ, Jones DH, Williams CJ, Whitehouse JM. Involvement of the ileocaecal region by non-Hodgkin's lymphoma in adults: clinical features and results of treatment. Br J Cancer. 1989, 60:366-9. 10.1038\/bjc.1989.286","journal-title":"Br J Cancer"},{"key":"ref2","article-title":"Burkitt lymphoma","author":"Martin P","year":"2024","unstructured":"Martin P, Leonard JP. Burkitt lymphoma. Merck Manual Professional Version. 2024,","journal-title":"Merck Manual Professional Version"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann BC","year":"2006","unstructured":"Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006, 11:694-703. 10.1634\/theoncologist.11-6-694","journal-title":"Oncologist"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315434","article-title":"Experimental chemotherapy-induced mucositis: a scoping review guiding the design of suitable preclinical models","volume":"23","author":"Huang J","year":"2022","unstructured":"Huang J, Hwang AY, Jia Y, Kim B, Iskandar M, Mohammed AI, Cirillo N. Experimental chemotherapy-induced mucositis: a scoping review guiding the design of suitable preclinical models. Int J Mol Sci. 2022, 23:15434. 10.3390\/ijms232315434","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70351","article-title":"Clinical risk factors for high-dose methotrexate-induced oral mucositis following individualized dosing","volume":"13","author":"Hu Z","year":"2024","unstructured":"Hu Z, Escalera-Joy AM, Ashcraft E, Acharya R, Jeha S, Cheng C, Pui CH. Clinical risk factors for high-dose methotrexate-induced oral mucositis following individualized dosing. Cancer Med. 2024, 13:70351. 10.1002\/cam4.70351","journal-title":"Cancer Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01715-7","article-title":"Oral mucositis: the hidden side of cancer therapy","volume":"39","author":"Pulito C","year":"2020","unstructured":"Pulito C, Cristaudo A, La Porta C, Zapperi S, Blandino G, Morrone A, Strano S. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020, 39:210. 10.1186\/s13046-020-01715-7","journal-title":"J Exp Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.33100","article-title":"MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","volume":"126","author":"Elad S","year":"2020","unstructured":"Elad S, Cheng KK, Lalla RV, et al.. MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020, 126:4423-4431.","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.20","article-title":"Clostridium difficile infection","volume":"2","author":"Smits WK","year":"2016","unstructured":"Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers. 2016, 2:16020. 10.1038\/nrdp.2016.20","journal-title":"Nat Rev Dis Primers"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser R","year":"2017","unstructured":"Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med. 2017, 377:2167-79. 10.1056\/NEJMra1609337","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi G","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, et al.. 2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome. Ann Rheum Dis. 2018, 77:808-18. 10.1136\/annrheumdis-2018-213225","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.28592","article-title":"MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","volume":"120","author":"Lalla RV","year":"2014","unstructured":"Lalla RV, Bowen J, Barasch A, et al.. MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014, 120:1453-1461.","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1318","article-title":"The pathobiology of mucositis","volume":"4","author":"Sonis ST","year":"2004","unstructured":"Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004, 4:277-84. 10.1038\/nrc1318","journal-title":"Nat Rev Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000180","article-title":"Mucositis. Pathobiology and management","volume":"27","author":"Villa A","year":"2015","unstructured":"Villa A, Sonis ST. Mucositis. Pathobiology and management. Curr Opin Oncol. 2015, 27:159-64. 10.1097\/CCO.0000000000000180","journal-title":"Curr Opin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.22529\/me.2021.6(2)08","article-title":"Mucocutaneous manifestation of low dose metotrexate toxicity, a purpose of a case (Article in Spanish)","volume":"6","author":"Gallmann AL","year":"2021","unstructured":"Gallmann AL, Ju\u00e1rez SC, Brusa JR, et al.. Mucocutaneous manifestation of low dose metotrexate toxicity, a purpose of a case (Article in Spanish). Methodo. 2021, 6:104-108. 10.22529\/me.2021.6(2)08","journal-title":"Methodo"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2020.04.001","article-title":"Methotrexate-induced mucositis as a sign of bone marrow toxicity: a retrospective study of clinical and epidemiological characteristics (Article in Spanish)","volume":"111","author":"Morgado-Carrasco D","year":"2020","unstructured":"Morgado-Carrasco D, Riquelme-Mc Loughlin C, Fust\u00e0-Novell X, Giavedoni P. Methotrexate-induced mucositis as a sign of bone marrow toxicity: a retrospective study of clinical and epidemiological characteristics (Article in Spanish). Actas Dermosifiliogr (Engl Ed). 2020, 111:436-9. 10.1016\/j.ad.2020.04.001","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-011-0143-6","article-title":"Acute renal failure post high dose methotrexate infusion successfully managed with high dose folinic acid and high flux dialysis","volume":"29","author":"Ramamoorthy SK","year":"2013","unstructured":"Ramamoorthy SK, Hephziba R. Acute renal failure post high dose methotrexate infusion successfully managed with high dose folinic acid and high flux dialysis. Indian J Hematol Blood Transfus. 2013, 29:90-2. 10.1007\/s12288-011-0143-6","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard SC","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016, 21:1471-82. 10.1634\/theoncologist.2015-0164","journal-title":"Oncologist"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20255","article-title":"High-dose methotrexate-induced mucocutaneous toxicity in children: a case series and review","volume":"68","author":"Widemann BC","year":"2011","unstructured":"Widemann BC, Balis FM, Kempf-Bielack B, et al.. High-dose methotrexate-induced mucocutaneous toxicity in children: a case series and review. Cancer Chemother Pharmacol. 2011, 68:1081-1086. 10.1002\/cncr.20255","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/403209-grade-4-mucositis-secondary-to-methotrexate-use-in-a-pediatric-patient-with-stage-iv-burkitt-lymphoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T13:35:20Z","timestamp":1756128920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/403209-grade-4-mucositis-secondary-to-methotrexate-use-in-a-pediatric-patient-with-stage-iv-burkitt-lymphoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.90944","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,25]]}}}